Table 2.
MDS patients and MPN patients’ characteristics.
| Characteristics (MDS) | SF3B1 WT | SF3B1 p.Lys700Glu | p Value | ||
|---|---|---|---|---|---|
| (n = 43; 75.4%) | (n = 14; 24.6%) | ||||
| n | % | n | % | ||
| Age (years) | ns | ||||
| Median (range) | 76 (31–94) | 74 (51–83) | |||
| Sex | ns | ||||
| Male | 28 | 65.1 | 7 | 50.0 | |
| Female | 15 | 34.9 | 7 | 50.0 | |
| WHO Classification | **** | ||||
| RS | 4 | 9.3 | 12 | 85.7 | |
| SLD | 9 | 20.9 | 0 | 0.0 | |
| MLD | 14 | 32.6 | 2 | 14.3 | |
| 5q- | 3 | 7.0 | 0 | 0.0 | |
| EB1/EB2 | 8 | 18.6 | 0 | 0.0 | |
| na | 5 | 11.6 | 0 | 0.0 | |
| IPSS-R | ns | ||||
| very low/low | 24 | 55.8 | 11 | 78.6 | |
| intermediate | 10 | 23.3 | 3 | 21.4 | |
| high/very high | 6 | 14.0 | 0 | 0.0 | |
| na | 3 | 7.0 | 0 | 0.0 | |
| WT1/104ABL1 copies | * | ||||
| normal | 13 | 30.2 | 10 | 71.4 | |
| high | 23 | 53.5 | 3 | 21.4 | |
| na | 7 | 16.3 | 1 | 7.1 | |
| Characteristics (MPN) | n = 33 | ||||
| n | % | ||||
| Age (years) | |||||
| Median (range) | 73 (52–88) | ||||
| Sex | |||||
| Male | 14 | 42.4 | |||
| Female | 19 | 57.6 | |||
| SF3B1 status | |||||
| WT | 32 | 97.0 | |||
| p.Lys700Glu | 1 | 3.0 | |||
| MPN type | |||||
| PV | 6 | 18.2 | |||
| ET | 0 | 0.0 | |||
| MF | 27 | 81.8 | |||
| MF evolution | |||||
| PMF | 11 | 40.7 | |||
| PPV-MF | 8 | 29.6 | |||
| PET-MF | 8 | 29.6 | |||
| WT1/104ABL1 copies | |||||
| normal | 5 | 15.2 | |||
| high | 27 | 81.8 | |||
| na | 1 | 3.0 | |||
Abbreviations: MDS, myelodysplastic syndromes; wt, wild-type; n, number; RS, ring sideroblast; SLD, single lineage dysplasia; MLD, multilineage dysplasia; EB, excess blasts; na, not available; MPN, myeloproliferative neoplasms; PV, polycythemia vera; ET, essential thrombocythemia; MF, myelofibrosis; PMF, primary MF; PPV, post-PV; PET, post-ET. All the analysis with confidence level major of 95% are indicated like significant and marked as followed: * p ≤ 0.05; **** p ≤ 0.0001; ns, not significant.